Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eisai Inc.
Jonsson Comprehensive Cancer Center
ImmunityBio, Inc.
M.D. Anderson Cancer Center
NeoTX Therapeutics Ltd.
Exelixis
Cancer Research UK
Carisma Therapeutics Inc
Salubris Biotherapeutics Inc
ImmunoVaccine Technologies, Inc. (IMV Inc.)